| Autor: |
Aso, Yoshimasa, Takada, Yoshihisa, Tomotsune, Ken, Chiba, Yasuko, Matsumura, Mihoko, Jojima, Teruo, Sato, Minoru, Fujita, Nobuya, Kuroda, Hisamoto, Murano, Shunichi, Usui, Isao |
| Zdroj: |
International Journal of Clinical Practice; Apr2021, Vol. 75 Issue 4, p1-8, 8p |
| Abstrakt: |
Aim: We compared the efficacy and safety of insulin degludec/insulin aspart co‐formulation (IDegAsp) twice‐daily to a free combination of basal insulin degludec and GLP‐1 receptor agonist liraglutide (IDeg + Lira) once‐daily for patients with inadequately controlled type 2 diabetes on insulin therapy and oral antidiabetic drugs. Subjects and Methods: Eligible patients were randomly allocated at a 1:1 ratio to receive either the once‐daily dual injection of IDeg + Lira (n = 24) or twice‐daily single injection of IDegAsp (n = 28). The primary endpoints were as follows: HbA1c changes over 52 weeks of treatment and the percentage of participants achieving HbA1c < 7.0% at week 52. Results: After 52 weeks, HbA1c decreased by 0.3% in the IDegAsp group and by 0.7% in the IDeg + Lira group. The HbA1c reduction was greater in the IDeg + Lira group than in the IDegAsp group. 19% of patients on IDegAsp versus 40% on IDeg + Lira achieved HbA1c < 7.0%. Pre‐breakfast and pre‐dinner blood glucose at 52 weeks were significantly lower in the IDeg + Lira group than in the IDegAsp group. The reduction in body mass index (BMI) was greater in the IDeg + Lira group than in the IDegAsp group throughout the study period. The confirmed hypoglycaemia rates were 1.32 and 0.69 per patient/year of exposure to IDegAsp and IDeg + Lira, respectively. Conclusions: In patients with inadequately controlled type 2 diabetes on insulin therapy and oral antidiabetic drugs, treatment with the once‐daily dual injection of IDeg + Lira compared with the twice‐daily single injection of IDegAsp showed no significant difference in glycaemic control but statistically superior weight loss. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
